ACTR2

Across TCGA pan-cancer cohorts, ACTR2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ACTR2 data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher ACTR2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ACTR2 expression acts as an unfavorable survival marker, although some lineages such as OV and LSCC show a favorable association.

GBM, LUAD, and OV are the cancer types where ACTR2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Tertile	All	0.353	0.745	<.001	22	view →
LUAD	OS	Median	III,IV	0.264	0.684	.017	10	view →
OV	DFS	Median	All	1.000	0.864	.035	4	view →
CCRCC	DFS	Quartile	III,IV	0.310	0.710	.040	3	view →
PDAC	DFS	Tertile	IV	0.199	0.752	.024	3	view →
LSCC	DFS	Tertile	II,III,IV	1.000	0.498	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ACTR2–GBM (OS)

Open the GBM breakdown →